Alaunos Therapeutics Inc. (NASDAQ: TCRT) stock jumped 8.39% on Friday to $1.68 against a previous-day closing price of $1.55. With 3.3 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.13 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.7800 whereas the lowest price it dropped to was $1.5410. The 52-week range on TCRT shows that it touched its highest point at $2.43 and its lowest point at $0.41 during that stretch. It currently has a 1-year price target of $3.70. Beta for the stock currently stands at 0.52.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TCRT was up-trending over the past week, with a rise of 41.18%, but this was up by 24.44% over a month. Three-month performance surged to 122.60% while six-month performance rose 75.57%. The stock lost -24.32% in the past year, while it has gained 54.13% so far this year. A look at the trailing 12-month EPS for TCRT yields -0.31 with Next year EPS estimates of -0.25. For the next quarter, that number is -0.07. This implies an EPS growth rate of 3.70% for this year and -13.00% for next year.
Float and Shares Shorts:
At present, 214.95 million TCRT shares are outstanding with a float of 192.88 million shares on hand for trading. On Jul 14, 2022, short shares totaled 28.87 million, which was 13.37% higher than short shares on Jun 14, 2022. In addition to Mr. Kevin S. Boyle Sr. as the firm’s CEO & Director, Mr. Michael Wong serves as its VP of Fin. & Principal Accounting Officer.
Through their ownership of 53.73% of TCRT’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 39.49% of TCRT, in contrast to 21.61% held by mutual funds. Shares owned by individuals account for 11.60%. As the largest shareholder in TCRT with 7.02% of the stake, MSD Partners LP holds 15,151,516 shares worth 15,151,516. A second-largest stockholder of TCRT, BlackRock Fund Advisors, holds 14,927,143 shares, controlling over 6.91% of the firm’s shares. Discovery Capital Management LLC is the third largest shareholder in TCRT, holding 14,013,093 shares or 6.49% stake. With a 2.69% stake in TCRT, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 5,807,002 shares are owned by the mutual fund manager. The JPMorgan Funds – Thematics – Gene, which owns about 1.66% of TCRT stock, is the second-largest Mutual Fund holder. It holds 3,573,670 shares valued at 4.43 million. Vanguard Extended Market Index Fu holds 1.43% of the stake in TCRT, owning 3,097,222 shares worth 3.84 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TCRT since 6 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With TCRT analysts setting a high price target of $7.50 and a low target of $1.50, the average target price over the next 12 months is $3.70. Based on these targets, TCRT could surge 346.43% to reach the target high and fall by -10.71% to reach the target low. Reaching the average price target will result in a growth of 120.24% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. TCRT will report FY 2022 earnings on 03/07/2023. Analysts have provided yearly estimates in a range of -$0.19 being high and -$0.27 being low. For TCRT, this leads to a yearly average estimate of -$0.22. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Alaunos Therapeutics Inc. surprised analysts by $0.00 when it reported -$0.05 EPS against a consensus estimate of -$0.05. The surprise factor in the prior quarter was $0.03. Based on analyst estimates, the high estimate for the next quarter is -$0.04 and the low estimate is -$0.05. The average estimate for the next quarter is thus -$0.05.
Summary of Insider Activity:
Insiders traded TCRT stock several times over the past three months with 9 Buys and 0 Sells. In these transactions, 440,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 18 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 1,673,770 while 20,132 shares were sold.